Nanoform Finland (OSTO:NANOFS) Debt-to-Equity : 0.09 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Nanoform Finland Debt-to-Equity?

Nanoform Finland's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was kr11.79 Mil. Nanoform Finland's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was kr58.20 Mil. Nanoform Finland's Total Stockholders Equity for the quarter that ended in Dec. 2023 was kr748.87 Mil. Nanoform Finland's debt to equity for the quarter that ended in Dec. 2023 was 0.09.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Nanoform Finland's Debt-to-Equity or its related term are showing as below:

OSTO:NANOFS' s Debt-to-Equity Range Over the Past 10 Years
Min: -3.05 Med: 0.1 Max: 1.28
Current: 0.09

During the past 8 years, the highest Debt-to-Equity Ratio of Nanoform Finland was 1.28. The lowest was -3.05. And the median was 0.10.

OSTO:NANOFS's Debt-to-Equity is ranked better than
61.78% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs OSTO:NANOFS: 0.09

Nanoform Finland Debt-to-Equity Historical Data

The historical data trend for Nanoform Finland's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanoform Finland Debt-to-Equity Chart

Nanoform Finland Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.46

0.11

0.09

0.08

0.09

Nanoform Finland Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.08	0.08	0.09	0.09	0.09

Competitive Comparison of Nanoform Finland's Debt-to-Equity

For the Biotechnology subindustry, Nanoform Finland's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nanoform Finland's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanoform Finland's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Nanoform Finland's Debt-to-Equity falls into.

Nanoform Finland Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Nanoform Finland's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(11.79	+	58.201)	/	748.872
	=	0.09

Nanoform Finland's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(11.79	+	58.201)	/	748.872
	=	0.09

Nanoform Finland (OSTO:NANOFS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Nanoform Finland Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Nanoform Finland's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanoform Finland (OSTO:NANOFS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanoform Finland PLC (OSTO:NANOFS) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

NANOFH:Finland 4YL:Germany

Address

Cultivator II, Viikinkaari 4, Helsinki, FIN, 00790

Website

https://www.nanoform.com

Nanoform Finland PLC is a nanoparticle medicine-enabling company. The company works together with pharma and biotech partners to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nano-forming services. Its patented and scalable Controlled Expansion of Supercritical Solutions (CESS) technology produces nano-formed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and by improving their bioavailability. Its technology provides novel opportunities in many value-enhancing drug delivery applications.

Nanoform Finland (OSTO:NANOFS) Headlines

No Headlines